Previously, Huilin Tang and colleagues, through a meta-analysis of several randomized controlled trials, suggested that SGLT2 inhibitors, especially empagliflozin, might increase the risk of bladder cancer (24), while Agata Ptaszynska and others (25) hold a different view. This evidence concerns the gene SLC5A2 and urinary bladder carcinoma.